+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Estrogens - pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation - Estring



Estrogens - pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation - Estring



Acta Obstetricia et Gynecologica Scandinavica. Supplement 163: 16-25



The consequences of diminished plasma estrogens in post-menopausal women are reviewed. The various options for estrogen replacement therapy are discussed with reference to the risks and benefits of estrogen therapy. The changes in estrogen plasma concentrations and the resulting systemic actions that occur following vaginal administration of different formulations of estrogens are reviewed with reference to Estring, a new intra-vaginal formulation designed to give sustained delivery of estradiol to the vaginal mucosa. The possibility of Estring causing local, adverse, actions on the endometrium and the reasons why this is unlikely are described.

(PDF emailed within 1 workday: $29.90)

Accession: 045995143

Download citation: RISBibTeXText

PMID: 8916471


Related references

Pharmacokinetic data on estradiol in light on the estring concept: Estradiol and estring pharmacokinetics. Acta Obstetricia et Gynecologica Scandinavica 75(SUPPL 163): 26-31, 1996

Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). Aids Research and Human Retroviruses 33(4): 339-346, 2016

Changes in coagulation proteins in postmenopausal women treated with Estring compared to conjugated equine estrogens in a vaginal cream. Maturitas 27(SUPPL ): 46, 1997

Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. American Journal of Obstetrics and Gynecology 152(8): 1099-1106, 1985

Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05). Journal of Acquired Immune Deficiency Syndromes 77(2): 175-182, 2017

A new method for the separation of androgens from estrogens and for the partition of estriol from the estrone-estradiol fraction with special reference to the identification and quantitative microdetermination of estrogens by ultraviolet absorption spectrophotometry. Journal of Biological Chemistry 174(2): 523-554, 1948

Pharmacokinetics and pharmacodynamics of transdermal administration of 17 beta estradiol after oophorectomy and during menopause. Acta Endocrinologica Supplementum 111(274): 3-4, 1986

Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. Journal of Pharmaceutical Sciences 107(12): 3179-3186, 2018

Diurnal variation in pharmacokinetics and pharmacodynamics of alprazolam after administration of a sustained release formulation. Pharmaceutical Research (New York) 10(10 SUPPL ): S362, 1993

Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. American Journal of Medicine 91(6a): 45s-50s, 1991

Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg). Contraception 84(6): 565-570, 2012

Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. European Journal of Drug Metabolism and Pharmacokinetics 34(3-4): 133-142, 2010

Pharmacokinetics and pharmacodynamics of a slow-release formulation of diltiazem after the administration of a single and repeated doses to healthy volunteers. Biopharmaceutics & Drug Disposition. 15(3): 227-242, 1994

A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. American Journal of Obstetrics and Gynecology 180(5): 1072-1079, 1999

A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. American Journal of Obstetrics and Gynecology 174(1 PART 1): 85-92, 1996